Universidade de Santiago de Compostela-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211